期刊文献+

抗凝血药与抗血小板药治疗的药学监护 被引量:19

Pharmaceutical Care in the Therapy of Anticoagulant and Antiplatelet Drug
原文传递
导出
摘要 目的:作为抗血栓性疾病和抗血小板治疗的一支奇葩,抗血小板药进展十分迅速,其临床应用和评价日趋活跃,本文总结其作用优势和药学监护。方法:采用国内、外文献综述方法。结果及结论:在大量的临床研究中,抗凝血药和抗血小板药显示了良好效果,但其合理和安全的应用尤为重要。 OBJECTIVE: To summarize the advantage and pharmaceutical care of antiplatelet drug because antiplatelet drug has satisfactory effect on thrombotic disease and platelet disorder with rapid development and sound clinical utilization and evaluation. METHODS: Literature review method was adopted to analyze medical literatures at home and abroad. RESULTS&CONCLUSION: In the large number of clinical studies, anticoagulant and antiplatelet drug have sound efficacy. Therefore it is important to use anticoagulant and antiplatelet drug rationally and safely.
作者 张石革
出处 《中国药房》 CAS CSCD 北大核心 2010年第10期944-947,共4页 China Pharmacy
关键词 抗凝血药 抗血小板药 药学监护 合理用药 Anticoagulant Antiplatelet drug Pharmaceutical care Rational use of drug
  • 相关文献

参考文献14

  • 1ESPRIT Study Group.Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT) : randomised controlled trial[J].Lancet, 2006, 367 (9 523):1 665.
  • 2Bhatt DL, Topoi EJ.Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rational and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial[J]. Am Heart J,2004,148(2) : 263.
  • 3Matetzky S, Shenkman B, Guetta V, et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J].Circulation, 2004,109(25) : 3 171.
  • 4Kandzari DE, Berger PB, Kastrati A, et al.lnfluence of treatment duration with a 600 mg dose of clopidogrel before percutaneous coronary revascularization[J]JAm Coll Cardiol , 2004 , 44 (11) : 2 133.
  • 5Bukow SC, Daffertshofer M, Hennerici MG.Tirofiban for the treatment of ischaemic stroke[J].Expert Opin Pharmacother, 2006,7(1) : 73.
  • 6Bhatt DL, Scheiman J, Abraham NS, et al.ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents[J].JAm Coll Cardiol, 2008,52 (18) : 1 502.
  • 7孙艺红,胡大一.阿司匹林与胃肠道出血:我们共同面对的问题[J].中华内科杂志,2009,48(2):89-90. 被引量:8
  • 8Antithrombitic TC.Collaborative Meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and strock in high risk patients[J].BMJ, 2002,324(7 342) : 71.
  • 9Hallas J, Dall M, Andries A, et al.Use of single and combined anti-throbotic therapy and risk of serious upper gastrointestinal bleeding: population based casecontrol study[J].BMJ, 2006,11 ( 3 ): 1.
  • 10Collet JP, Hulot JS, Pena A, et al.Cytochrome P4502C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study[J].Lancet, 2009,373 (9 600 ) : 309.

二级参考文献12

  • 1Bhatt DL, Seheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coil Cardiol,2008,52:1502- 1517.
  • 2Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction : a cohort study [ J ]. Lancet, 2009,373 (9 660) :309.
  • 3Mega JL, Close SL, Wiviott SD, et al. Cytochrome P- 450 polymorphisms and response to clopidogrel [ J ]. N Engl J Med,2009,360(4):354.
  • 4Simon T, Verstuyft C, Mary- Krause M, et al. Geneti determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med ,2009,360(4) :363.
  • 5Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss- of- function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J, 2009,30(8) :916.
  • 6Angiolillo D J, Fernandez - Ortiz A, Bemardo E, et al. PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation [ J] . Blood Coagul Fibrinol~'sis, 2004,15 ( 1 ) : 89.
  • 7Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence[J].J Am Coll Cardiol, 2005,45(8) :1 157.
  • 8Chen L, Qin S, Xie J, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of China's Mainland [ J ] . Pharmacogenomics, 2008,9(6) :691.
  • 9Garcia- Barcelo M, Chow LY, Kum Chiu HF, et al. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population [ J ]. Clinical Chemistry, 1999,45 ( 12 ) : 2 273.
  • 10Roden DM, Stein CM. Clopidogrel and the Concept of High - Risk Pharmacokinetics [ J ]. Circulation, 2009, 119 ( 16 ) : 2 127.

共引文献16

同被引文献182

引证文献19

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部